Volume 21 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(1): 104-107
YU Hui-juan, XING Li-li, YANG Fan, LI Guang-ming. Low-dose contrast-enhanced ultrasound combined with serum microRNA-1469 level in the diagnosis of benign and malignant liver tumours[J]. Chinese Journal of General Practice, 2023, 21(1): 104-107. doi: 10.16766/j.cnki.issn.1674-4152.002823
Citation: YU Hui-juan, XING Li-li, YANG Fan, LI Guang-ming. Low-dose contrast-enhanced ultrasound combined with serum microRNA-1469 level in the diagnosis of benign and malignant liver tumours[J]. Chinese Journal of General Practice, 2023, 21(1): 104-107. doi: 10.16766/j.cnki.issn.1674-4152.002823
shu

Low-dose contrast-enhanced ultrasound combined with serum microRNA-1469 level in the diagnosis of benign and malignant liver tumours

doi: 10.16766/j.cnki.issn.1674-4152.002823
  • 1.

    Department of Ultrasound Medical Imaging, the Seventh People' s Hospital of Zhengzhou, Zhengzhou, Henan 450000, China

Funds:

 2018020849

  • Received Date: 2022-03-11
    Available Online: 2023-04-07
    Abstract
  •   Objective  To analyze the value of low dose contrast-enhanced ultrasound combined with serum microRNA-1469 in the diagnosis of benign and malignant neoplasms in liver.  Methods  A retrospective analysis of the clinical data of 103 patients with liver tumours who were admitted from January 2017 to January 2020 in Seventh People' s Hospital of Zhengzhou was conducted. According to benign and malignant tumors, they were divided into benign tumor group (50 cases) and malignant tumor group (53 cases). Low-dose contrast-enhanced ultrasonography was performed at admission, and the level of serum miR-1469 was detected. The value of low-dose contrast-enhanced ultrasound combined with serum miR-1469 in the diagnosis of benign and malignant liver tumours was evaluated.  Results  The peak intensity of contrast-enhanced ultrasound in the benign tumour group [(127.84±14.59) dB] was lower than that in the malignant tumour group [(186.36±18.14) dB, P < 0.05]. In the benign tumour group, the peak time of contrast-enhanced ultrasound [(60.28±6.52) s] was higher than that in the malignant tumour group [(40.75±4.87) s, P < 0.05], and the expression level of miR-1469 (5.74±0.62) was higher than that of the malignant tumour group (0.82±0.08, P < 0.05). ROC analysis showed that the peak intensity and peak time of contrast-enhanced ultrasound were 155.32 dB and 42.34 s, respectively. The area under the curve (AUC) of liver malignant tumours was 0.791 and 0.801, respectively, and the AUC of peak time was high. The best cut-off point of miR-1469 in the diagnosis of liver malignant tumours was 0.88. The sensitivity, AUC and Youden index of combined diagnosis of contrast-enhanced ultrasound combined with mir-1469 were 74.46%, 0.912 and 0.640, respectively.  Conclusion  Low-dose contrast-enhanced ultrasound combined with serum miR-1469 can be used to diagnose benign and malignant liver tumours. The diagnostic efficiency is better than that of single diagnosis, and the clinical application value is higher.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    TU H B, CHEN L H, LIN J L, et al. Liver cancer confirmation by contrast-enhanced ultrasound coupled with magnetic resonance imaging: case report of liver inflammation misdiagnosed as atypical liver cancer[J]. J Ultras Med, 2020, 39(7): 1453-1457. doi: 10.1002/jum.15233
    [2]
    LI B, LI B A, GUO T S, et al. Application value of mass spectrometry in the differentiation of benign and malignant liver tumors[J]. Med Sci Monit, 2017, 4(23): 1636-1644.
    [3]
    陈恩利, 楼俊晓, 王镇, 等. lncRNA GIHCG通过调节miR-429在原发性肝癌发生发展中的作用[J]. 中华全科医学, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790

    CHEN E L, LOU J X, WANG Z, et al. Role of lncRNA GIHCG in the development of primary liver cancer by regulating miR-429[J]. Chinese Journal of General Practice, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790
    [4]
    于福盈, 王春光, 辛旺, 等. 超声造影联合血清学检测诊断肝脏良恶性肿瘤[J]. 肝脏, 2019, 24(2): 172-174. doi: 10.14000/j.cnki.issn.1008-1704.2019.02.021

    YU F Y, WANG C G, XIN W, et al. Diagnosis of benign and malignant liver tumors by contrast-enhanced ultrasound combined with serology[J]. Chinese Hepatology, 2019, 24(2): 172-174. doi: 10.14000/j.cnki.issn.1008-1704.2019.02.021
    [5]
    ZHENG Q, ZHANG J C, WANG Z, et al. Assessment of angiogenesis in rabbit orthotropic liver tumors using three-dimensional dynamic contrast-enhanced ultrasound compared with two-dimensional DCE-US[J]. Jpn J Radiol, 2019, 37(10): 701-707. doi: 10.1007/s11604-019-00861-z
    [6]
    LIU J, WANG C F, LIU X Y, et al. Low expression of miR-1469 predicts disease progression and unfavorable post-surgical clinical outcomes in patients with esophageal squamous cell cancer[J]. Oncol Lett, 2017, 13(6): 4469-4474. doi: 10.3892/ol.2017.5957
    [7]
    LEE J H, SUH J H, KANG H J, et al. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance[J]. EBio Med, 2020, 10(58): 102926. DOI: 10.1016/j.ebiom.2020.102926.
    [8]
    俞南松, 严培军, 郑媛媛, 等. 射频消融联合索拉非尼治疗中晚期肝癌对患者肝功能的影响及疗效分析[J]. 中华全科医学, 2018, 16(5): 754-756. doi: 10.16766/j.cnki.issn.1674-4152.000205

    YU N S, YAN P J, ZHENG Y Y, et al. Effect of radiofrequency ablation combined with sorafenib on liver function in patients with advanced hepatic carcinoma[J]. Chinese Journal of General Practice, 2018, 16(5): 754-756. doi: 10.16766/j.cnki.issn.1674-4152.000205
    [9]
    MARRERO J A, KULIK L M, SIRLIN C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723-750. doi: 10.1002/hep.29913
    [10]
    ZHANG Q, LOU Y, BAI X L, et al. Immunometabolism: a novel perspective of liver cancer microenvironment and its influence on tumor progression[J]. World J Gastroenterol, 2018, 24(31): 3500-3512. doi: 10.3748/wjg.v24.i31.3500
    [11]
    YIN J, QIU J J, QIAN W, et al. A radiomics signature to identify malignant and benign liver tumors on plain CT images[J]. J Xray Sci Technol, 2020, 28(4): 683-694.
    [12]
    BURENINA O Y, LAZAREVICH N L, KUSTOVA I F, et al. Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors[J]. J Cancer Res Clin Oncol, 2020, 147(1): 49-59.
    [13]
    杨小芳, 蔡春晓, 刘阳桦. 超声造影联合血清CEA, CA72-4对卵巢良恶性肿瘤鉴别诊断的价值[J]. 现代肿瘤医学, 2020, 28(9): 1508-1512. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202009019.htm

    YANG X F, CAI C X, LIU Y Y. Value of contrast-enhanced ultrasound combined with serum CEA and CA72-4 in differential diagnosis of benign and malignant ovarian tumors[J]. Journal of Modern Oncology, 2020, 28(9): 1508-1512. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202009019.htm
    [14]
    GONG E, PAULY J M, WINTERMARK M, et al. Deep learning enables reduced gadolinium dose for contrast-enhanced brain MRI[J]. J Magn Reson Imaging, 2018, 48(2): 330-340. doi: 10.1002/jmri.25970
    [15]
    HE D, CHATTERJEE A, FAN X, et al. Feasibility of dynamic contrast-enhanced magnetic resonance imaging using low-dose gadolinium: comparative performance with standard dose in prostate cancer diagnosis[J]. Invest Radiol, 2018, 53(10): 609-615. doi: 10.1097/RLI.0000000000000466
    [16]
    LAADER A, BEIDERRWELLEN K, KRAFF O, et al. Non-enhanced versus low-dose contrast-enhanced renal magnetic resonance angiography at 7 T: a feasibility study[J]. Acta Radiol, 2018, 59(3): 296-304. doi: 10.1177/0284185117718399
    [17]
    AlAMOUDI A A, ALNOURY A, GAD H. miRNA in tumour metabolism and why could it be the preferred pathway for energy reprograming[J]. Brief Funct Genomics, 2018, 17(3): 157-169. doi: 10.1093/bfgp/elx023
    [18]
    LIU J, WANG C F, LIU X Y, et al. Low expression of miR-1469 predicts disease progression and unfavorable post-surgical clinical outcomes in patients with esophageal squamous cell cancer[J]. Oncol Lett, 2017, 13(6): 4469-4474.
    [19]
    王宇锋, 朱怡凤, 殷国志. 肝细胞癌中microRNA-1469表达及其对肝癌细胞生物学行为的影响[J]. 新乡医学院学报, 2019, 36(9): 806-814. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX201909003.htm

    WANG Y F, ZHU Y F, YIN G Z. Expression of microRNA-1469 and its function in hepatocellular carcinoma cells[J]. Journal of Xinxiang Medical University, 2019, 36(9): 806-814. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX201909003.htm
    [20]
    闫珊玲, 卢强, 郑红, 等. 超声造影时间-强度曲线联合血清学检测在肝脏肿瘤良恶性鉴别诊断中的价值[J]. 实用医院临床杂志, 2018, 15(1): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201801013.htm

    YAN S L, LU Q, ZHENG H, et al. Clinical value of time-intensity curve of contrast-enhanced ultrasound combined with serologic tests in differential diagnosis of liver benign and malignant tumors[J]. Practical Journal of Clinical Medicine, 2018, 15(1): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201801013.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (220) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return